NUZ neurizon therapeutics limited

Ann: Neurizon to present Q3 FY2025 Results, page-4

  1. 1,731 Posts.
    lightbulb Created with Sketch. 543
    Yea the presentations used to say possible FDA approval in 2026 based on phase 2 results. I'd say that's now 2027 with the 6-9 month delay.

    So I take it that there is an interim readout for a certain number of patients that corresponds to the phase 2 of the phase 2/3 trial?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
0.000(0.00%)
Mkt cap ! $83.69M
Open High Low Value Volume
18.0¢ 18.0¢ 17.0¢ $67.96K 391.1K

Buyers (Bids)

No. Vol. Price($)
12 640049 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 50000 1
View Market Depth
Last trade - 16.10pm 28/07/2025 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.